Burkitt Lymphoma: FDA Updates

December 2, 2021 – The U.S. Food and Drug Administration (FDA) announced it has approved rituximab (RITUXAN, Genentech, Inc.), a monoclonal antibody, in combination with chemotherapy for pediatric patients aged at least 6 months to 18 years with previously untreated, advanced staged, CD20-positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), and Burkitt-like lymphoma (BLL). More information.